Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT06614192
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
- NCT06614192 ↗
- Active, not recruiting
- AbbVie
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
This is what we have already indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Telisotuzumab Adizutecan
- Arms
- Telisotuzumab Adizutecan Dose A · Experimental
- Telisotuzumab Adizutecan Dose B · Experimental
- Enrollment
- 74
- Primary outcomes
- Percentage of Participants with Adverse Events (AE)s
- Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator
- Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator
- Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator
- Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- AbbVie
- Start
- Nov 8, 2024
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06614192 · updated Sep 23, 2026